Similarly, where the IBAT inhibitor maralixibat is used in patients with Alagille’s syndrome, the time point at which this pharmacological option is commenced may be important for controlling the HCC risk, particularly since the HCC risk in Alagille’s syndrome is thought to be related to the development of cirrhosis. Here, SLC10A2 is linked to Alagille syndrome.